Company profile: Frontida BioPharm
1.1 - Company Overview
Company description
- Provider of contract development and manufacturing services for biopharmaceutical companies, supporting scale-up and commercial manufacture of immediate and controlled release oral solid dose products, with capabilities to manufacture Highly Potent Active Ingredient products.
Products and services
- Analytical Services: Delivers laboratory-grade, comprehensive analytical testing and stability studies across various temperature ranges to characterize and monitor pharmaceutical product performance
- Commercial Manufacturing: Engineers commercial-scale pharmaceutical products through granulation, mixing, fluid bed processing, tableting, and capsule filling to enable reliable commercial supply
- Formulation Development: Architects custom-engineered oral dosage forms featuring taste masking and customized drug release to enhance patient-centered administration and therapeutic adherence
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Frontida BioPharm
Leukocare
HQ: Germany
Website
- Description: Provider of biopharmaceutical formulation development services operating at the interface of drug substance and drug product, combining bioinformatics, artificial intelligence and data science. Offerings include drug substance characterization, developability assessment, particle characterization, stability studies, and in silico analytics to optimize and accelerate development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leukocare company profile →
Emergent Health
HQ: United States
Website
- Description: Provider of regenerative medicine, including nutraceuticals and phytonutritionals, developing and selling products such as Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent Health company profile →
AnovoRx
HQ: United States
Website
- Description: Provider of specialty pharmacy and access services for ultra-rare medications, offering 3PL/specialty distribution, patient support (benefits investigation, prior authorization and appeals, case management), reimbursement programs, clinical assessment and adherence management, adverse event reporting, and product complaint and recall management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnovoRx company profile →
Chiltern
HQ: United States
Website
- Description: Provider of clinical development, scientific services, and collaborative technologies for pharmaceutical and biotech companies as a contract research organization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chiltern company profile →
Gelpell
HQ: Switzerland
Website
- Description: Provider of manufacturing for food supplements and nutrients, offering soft gelatin capsules for oily and semi-solid preparations; Gelpell® beads for slow, even release and improved bioavailability; hard capsules with powders or Gelpell® beads; plant-based pea-starch soft capsules; blister packaging compliant with pharmaceutical standards; and bulk product supply.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gelpell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Frontida BioPharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Frontida BioPharm
2.2 - Growth funds investing in similar companies to Frontida BioPharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Frontida BioPharm
4.2 - Public trading comparable groups for Frontida BioPharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →